{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:45:26Z","timestamp":1793173526866,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020211","name":"Austin Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020211","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06603-x","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:21:53Z","timestamp":1784276513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-7028","authenticated-orcid":false,"given":"Thomas","family":"McMaster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"McVeigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Khanaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Carll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixon T.","family":"Woon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"3","key":"6603_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/cancers18030527","volume":"18","author":"A Adika","year":"2026","unstructured":"Adika A, Zibelman M (2026) Perioperative immune-checkpoint inhibition in renal cell carcinoma: lessons learned and future directions. Cancers (Basel) 18(3):527","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6603_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers17020312","volume":"17","author":"Q Qin","year":"2025","unstructured":"Qin Q et al (2025) A review of neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Cancers (Basel) 17(2):312","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6603_CR3","doi-asserted-by":"publisher","first-page":"pe70641","DOI":"10.1002\/mco2.70641","volume":"7","author":"W Yang","year":"2020","unstructured":"Yang W et al (2020) Tislelizumab combined with axitinib in neoadjuvant treatment of locally advanced clear cell renal cell carcinoma: a single-center, phase II clinical study. MedComm 7(3):pe70641 2026","journal-title":"MedComm"},{"key":"6603_CR4","doi-asserted-by":"crossref","unstructured":"McKay RR et al (2025) Advanced Urologic Cancer Consensus Conference (AUC3) : Expert consensus on the management of renal cell and urinary tract cancers. CA Cancer J Clin, 2026. 76(1): p. e70052","DOI":"10.3322\/caac.70070"},{"issue":"5","key":"6603_CR5","first-page":"E199","volume":"19","author":"XG Robledo","year":"2025","unstructured":"Robledo XG, Garc\u00eda-Perdomo HA (2025) Neoadjuvant systemic therapy in managing locally advanced renal cancer before surgery a systematic review and meta-analysis. Can Urol Assoc J 19(5):E199\u2013e204","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"6603_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s43018-025-00922-5","volume":"6","author":"MA Bilen","year":"2025","unstructured":"Bilen MA et al (2025) Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nat Cancer 6(3):432\u2013444","journal-title":"Nat Cancer"},{"issue":"6","key":"6603_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","volume":"81","author":"MI Carlo","year":"2022","unstructured":"Carlo MI et al (2022) Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur Urol 81(6):570\u2013573","journal-title":"Eur Urol"},{"key":"6603_CR8","doi-asserted-by":"publisher","first-page":"104316","DOI":"10.1016\/j.critrevonc.2024.104316","volume":"196","author":"L Gu","year":"2024","unstructured":"Gu L et al (2024) Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: a systematic review and meta-analysis. Crit Rev Oncol Hematol 196:104316","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"6603_CR9","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","volume":"14","author":"JA Karam","year":"2023","unstructured":"Karam JA et al (2023) Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684","journal-title":"Nat Commun"},{"key":"6603_CR10","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.3390\/ijms22126290","volume":"22","author":"H-W Lee","year":"2021","unstructured":"Lee H-W (2021) Multidiscipline immunotherapy-based rational combinations for robust and durable efficacy in brain metastases from renal cell carcinoma. Int J Mol Sci 22:6290. https:\/\/doi.org\/10.3390\/ijms22126290","journal-title":"Int J Mol Sci"},{"key":"6603_CR11","unstructured":"BioRender (2026) Mechanism of action of key tyrosine kinase inhibitors and immune check point inhibitors against a turmour cell"},{"issue":"11","key":"6603_CR12","first-page":"e97247","volume":"17","author":"F Abusal","year":"2025","unstructured":"Abusal F et al (2025) Neoadjuvant therapy to enable partial nephrectomy in patients with high-complexity or locally advanced non-metastatic renal cell carcinoma: a systematic review and meta-analysis. Cureus 17(11):e97247","journal-title":"Cureus"},{"issue":"4","key":"6603_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/KCA-220012","volume":"6","author":"JO Jones","year":"2022","unstructured":"Jones JO et al (2022) Activity of immunotherapy regimens on primary renal tumours: a systematic review. Kidney Cancer 6(4):221\u2013236","journal-title":"Kidney Cancer"},{"key":"6603_CR14","doi-asserted-by":"publisher","first-page":"1705494","DOI":"10.3389\/fimmu.2025.1705494","volume":"16","author":"K Chen","year":"2025","unstructured":"Chen K et al (2025) Presurgical molecular therapy for renal cell carcinoma with venous tumor thrombus: a systematic review and meta-analysis. Front Immunol 16:1705494","journal-title":"Front Immunol"},{"issue":"10","key":"6603_CR15","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1016\/S1470-2045(25)00345-6","volume":"26","author":"JP Blackmur","year":"2025","unstructured":"Blackmur JP et al (2025) Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium. Lancet Oncol 26(10):e536\u2013e546","journal-title":"Lancet Oncol"},{"issue":"3","key":"6603_CR16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143\u2013e152","journal-title":"Lancet Oncol"},{"issue":"10","key":"6603_CR17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jamaoncol.2016.1197","volume":"2","author":"T Powles","year":"2016","unstructured":"Powles T et al (2016) Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncol 2(10):1303\u20131309","journal-title":"JAMA Oncol"},{"issue":"2","key":"6603_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","volume":"5","author":"A Bex","year":"2019","unstructured":"Bex A et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 5(2):164\u2013170","journal-title":"JAMA Oncol"},{"issue":"5","key":"6603_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bju.14581","volume":"123","author":"C Lebacle","year":"2019","unstructured":"Lebacle C et al (2019) Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int 123(5):804\u2013810","journal-title":"BJU Int"},{"key":"6603_CR20","doi-asserted-by":"publisher","first-page":"S698","DOI":"10.1016\/j.annonc.2021.08.072","volume":"32","author":"G De Velasco","year":"2021","unstructured":"De Velasco G et al (2021) 676P CABOPRE: a phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC). Ann Oncol 32:S698\u2013S699","journal-title":"Ann Oncol"},{"key":"6603_CR21","doi-asserted-by":"publisher","unstructured":"Stewart GD, Welsh SJ, Ursprung S et al (2022) A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer 127:1051\u20131060. https:\/\/doi.org\/10.1038\/s41416-022-01883-7","DOI":"10.1038\/s41416-022-01883-7"},{"issue":"4","key":"6603_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bju.16217","volume":"133","author":"K Hakimi","year":"2024","unstructured":"Hakimi K et al (2024) PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy. BJU Int 133(4):425\u2013431","journal-title":"BJU Int"},{"issue":"1","key":"6603_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","volume":"5","author":"MA Gorin","year":"2022","unstructured":"Gorin MA et al (2022) Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur Urol Oncol 5(1):113\u2013117","journal-title":"Eur Urol Oncol"},{"key":"6603_CR24","doi-asserted-by":"crossref","unstructured":"Gu L et al (2024) Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study, vol 9. Signal Transduction and Targeted Therapy, 1.","DOI":"10.1038\/s41392-024-01990-2"},{"key":"6603_CR25","doi-asserted-by":"crossref","unstructured":"Huang J et al (2024) Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: A single-arm, phase II trial. J Immunother Cancer 12:e008475","DOI":"10.1136\/jitc-2023-008475"},{"key":"6603_CR26","doi-asserted-by":"publisher","first-page":"S1636","DOI":"10.1016\/j.annonc.2025.09.112","volume":"36","author":"F Burgers","year":"2025","unstructured":"Burgers F et al (2025) LBA95 Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial. Ann Oncol 36:S1636\u2013S1637","journal-title":"Ann Oncol"},{"issue":"5suppl","key":"6603_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.2025.43.5_suppl.555","volume":"43","author":"MA Bilen","year":"2025","unstructured":"Bilen MA et al (2025) Phase 2 study of perioperative lenvatinib (L) with pembrolizumab (P) in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. J Clin Oncol 43(5suppl):555\u2013555","journal-title":"J Clin Oncol"},{"key":"6603_CR28","doi-asserted-by":"publisher","first-page":"S1603","DOI":"10.1016\/j.eururo.2025.09.3951","volume":"87","author":"X Zou","year":"2025","unstructured":"Zou X et al (2025) Efficacy and safety of neoadjuvant pazopanib plus sintilimab in renal cell carcinoma patients with high surgical complexity of partial nephrectomy: a phase II trial. Eur Urol 87:S1603","journal-title":"Eur Urol"},{"key":"6603_CR29","doi-asserted-by":"crossref","unstructured":"Bex A et al (2025) Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy. J Clin Oncol, 43(16)","DOI":"10.1200\/JCO.2025.43.16_suppl.4509"},{"issue":"7suppl","key":"6603_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.2026.44.7_suppl.513","volume":"44","author":"K Runcie","year":"2026","unstructured":"Runcie K et al (2026) Cyto-KIK: a phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib). J Clin Oncol 44(7suppl):513\u2013513","journal-title":"J Clin Oncol"},{"key":"6603_CR31","doi-asserted-by":"publisher","first-page":"S1602","DOI":"10.1016\/j.eururo.2025.09.3950","volume":"87","author":"YL Peng","year":"2025","unstructured":"Peng YL, Pei D, Zhiling Z (2025) Cadonilimab combined with lenvatinib for neoadjuvant therapy in early-stage renal cell carcinoma with indications for partial nephrectomy but high surgical risk: a prospective single-arm phase II clinical trial. Eur Urol 87:S1602","journal-title":"Eur Urol"},{"issue":"16","key":"6603_CR32","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2025.43.16_suppl.4541","volume":"43","author":"S Zhu","year":"2025","unstructured":"Zhu S, Quan C, Wei H (2025) Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study. J Clin Oncol 43(16):4541","journal-title":"J Clin Oncol"},{"issue":"17","key":"6603_CR33","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-16-2946","volume":"23","author":"AK Singh","year":"2017","unstructured":"Singh AK et al (2017) A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Cancer Res 23(17):5055\u20135065","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6603_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","volume":"110","author":"V Margulis","year":"2021","unstructured":"Margulis V et al (2021) Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial. Int J Radiat Oncol Biol Phys 110(4):1135\u20131142","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6603_CR35","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.ijrobp.2025.06.1178","volume":"123","author":"M Ali","year":"2025","unstructured":"Ali M et al (2025) Neoadjuvant pembrolizumab and stereotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): a phase II randomised clinical trial. Int J Radiat Oncol Biol Phys 123(1):S118\u2013S119","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"6603_CR36","doi-asserted-by":"publisher","first-page":"TPS488","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS488","volume":"42","author":"S Lakritz","year":"2024","unstructured":"Lakritz S et al (2024) Neoadjuvant pembrolizumab (PEMBRO) and axitinib (AXI) in renal cell carcinoma with associated inferior vena cava tumor thrombus (NEOPAX). J Clin Oncol 42(4):TPS488","journal-title":"J Clin Oncol"},{"issue":"6suppl","key":"6603_CR37","doi-asserted-by":"publisher","first-page":"TPS373","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS373","volume":"39","author":"M Dallos","year":"2021","unstructured":"Dallos M et al (2021) The SPARC-1 trial: a phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma. J Clin Oncol 39(6 suppl):TPS373","journal-title":"J Clin Oncol"},{"key":"6603_CR38","unstructured":"(2022) A phase II study of the safety and efficacy of neoadjuvant lenvatinib and pembrolizumab in patients with renal cell carcinoma and IVC tumor thrombus."},{"key":"6603_CR39","unstructured":"Single-center A (2021) Non-randomized controlled, single-arm, phase II clinical trial of pembrolizumab and axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal cell carcinoma (PANDORA)."},{"key":"6603_CR40","unstructured":"Phase II (2025) Trial of single agent belzutifan or pembrolizumab versus combination as neoadjuvant therapy in clear cell renal cell carcinoma (BLAZE). Merck S, Dohme LLC, (Ed)."},{"issue":"4","key":"6603_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2019.06.006","volume":"76","author":"RE De Bruijn","year":"2019","unstructured":"De Bruijn RE et al (2019) Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur Urol 76(4):437\u2013440","journal-title":"Eur Urol"},{"issue":"4","key":"6603_CR42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3892\/ol.2024.14295","volume":"27","author":"M Zhu","year":"2024","unstructured":"Zhu M et al (2024) Effects of neoadjuvant VEGF\u2013TKI treatment on surgery for renal cell carcinoma: a systematic review and meta\u2013analysis. Oncol Lett 27(4):162","journal-title":"Oncol Lett"},{"issue":"8","key":"6603_CR43","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf ME et al (2024) Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 25(8):1038\u20131052","journal-title":"Lancet Oncol"},{"issue":"5","key":"6603_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1803675","volume":"379","author":"A M\u00e9jean","year":"2018","unstructured":"M\u00e9jean A et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"47","key":"6603_CR45","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.18632\/oncotarget.27807","volume":"11","author":"G De Velasco","year":"2020","unstructured":"De Velasco G et al (2020) A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. Oncotarget 11(47):4457\u20134462","journal-title":"Oncotarget"},{"key":"6603_CR46","doi-asserted-by":"crossref","unstructured":"Choueiri Toni K et al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390(15):1359\u20131371","DOI":"10.1056\/NEJMoa2312695"},{"issue":"10358","key":"6603_CR47","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK et al (2022) Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400(10358):1103\u20131116","journal-title":"Lancet"},{"issue":"10379","key":"6603_CR48","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ et al (2023) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401(10379):821\u2013832","journal-title":"Lancet"},{"issue":"14","key":"6603_CR49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"J Motzer Robert","year":"2018","unstructured":"Motzer Robert J et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290","journal-title":"N Engl J Med"},{"issue":"9","key":"6603_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"K Choueiri Toni","year":"2021","unstructured":"Choueiri Toni K et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829\u2013841","journal-title":"N Engl J Med"},{"issue":"4","key":"6603_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","volume":"36","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK et al (2025) Avelumab\u2009+\u2009axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol 36(4):387\u2013392","journal-title":"Ann Oncol"},{"key":"6603_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euros.2024.02.001","volume":"63","author":"MF Meagher","year":"2024","unstructured":"Meagher MF et al (2024) Does the timing of cytoreductive nephrectomy impact outcomes? Analysis of REMARCC registry data for patients receiving tyrosine kinase inhibitor versus immune checkpoint inhibitor therapy. Eur Urol Open Sci 63:71\u201380","journal-title":"Eur Urol Open Sci"},{"issue":"21","key":"6603_CR53","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.3390\/cancers17213481","volume":"17","author":"C Saitta","year":"2025","unstructured":"Saitta C et al (2025) Propensity score-matched analysis of neoadjuvant vs. adjuvant therapy in renal cell carcinoma. Cancers (Basel) 17(21):3481","journal-title":"Cancers (Basel)"},{"issue":"8","key":"6603_CR54","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.3390\/curroncol29080429","volume":"29","author":"LM Cardenas","year":"2022","unstructured":"Cardenas LM et al (2022) Next wave of targets in the treatment of advanced renal cell carcinoma. Curr Oncol 29(8):5426\u20135441","journal-title":"Curr Oncol"},{"issue":"16suppl","key":"6603_CR55","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1200\/JCO.2022.40.16_suppl.4546","volume":"40","author":"E Jonasch","year":"2022","unstructured":"Jonasch E et al (2022) LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2\u03b1 inhibitor (HIF-2\u03b1), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data. J Clin Oncol 40(16suppl):4546\u20134546","journal-title":"J Clin Oncol"},{"issue":"8","key":"6603_CR56","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK et al (2024) Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med 391(8):710\u2013721","journal-title":"N Engl J Med"},{"issue":"16suppl","key":"6603_CR57","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1200\/JCO.2023.41.16_suppl.4553","volume":"41","author":"L Albiges","year":"2023","unstructured":"Albiges L et al (2023) Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1\/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1\/2 KEYMAKER-U03B study. J Clin Oncol 41(16suppl):4553\u20134553","journal-title":"J Clin Oncol"},{"key":"6603_CR58","unstructured":"An (2020) Open-label, randomized, phase 3 study of MK-6482 in combination with lenvatinib (MK-7902) vs cabozantinib in participants with advanced renal cell carcinoma who have progressed after prior anti-PD-1\/L1 therapy, I. Eisai, Editor"},{"key":"6603_CR59","unstructured":"Eisai I et al (2021) An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)"},{"key":"6603_CR60","unstructured":"Multicenter A (2022) Double-blind, randomized phase 3 study to compare the efficacy and safety of belzutifan (MK-6482) plus pembrolizumab (MK-3475) versus placebo plus pembrolizumab in the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) post nephrectomy (MK-6482-022)."},{"key":"6603_CR61","doi-asserted-by":"publisher","first-page":"175883592513178","DOI":"10.1177\/17588359251317846","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X et al (2025) Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol 17:17588359251317846","journal-title":"Ther Adv Med Oncol"},{"issue":"7suppl","key":"6603_CR62","first-page":"LBA418","volume":"44","author":"TK Choueiri","year":"2026","unstructured":"Choueiri TK et al (2026) Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study. J Clin Oncol 44(7suppl):LBA418\u2013LBA418","journal-title":"J Clin Oncol"},{"issue":"2","key":"6603_CR63","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bju.15600","volume":"130","author":"SJ Welsh","year":"2022","unstructured":"Welsh SJ et al (2022) Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. BJU Int 130(2):244\u2013253","journal-title":"BJU Int"},{"issue":"4","key":"6603_CR64","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28(4):704\u2013712","journal-title":"Nat Med"},{"issue":"1","key":"6603_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cancers16010047","volume":"16","author":"Y Tomita","year":"2023","unstructured":"Tomita Y et al (2023) Association of clostridium butyricum therapy using the live bacterial product CBM588 with the survival of patients with lung cancer receiving chemoimmunotherapy combinations. Cancers (Basel) 16(1):47","journal-title":"Cancers (Basel)"},{"issue":"17suppl","key":"6603_CR66","doi-asserted-by":"publisher","first-page":"LBA104","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA104","volume":"41","author":"H Ebrahimi","year":"2023","unstructured":"Ebrahimi H et al (2023) Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): a randomized clinical trial. J Clin Oncol 41(17suppl):LBA104\u2013LBA104","journal-title":"J Clin Oncol"},{"key":"6603_CR67","unstructured":"Phase IIID (2026) Blinded trial of immune-based therapy with a live biotherapeutic MO-03 or placebo for frontline therapy of advanced clear cell renal cell carcinoma [BioFront Trial], I. National Cancer."},{"issue":"5","key":"6603_CR68","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1021\/acs.molpharmaceut.4c00084","volume":"21","author":"Z Chen","year":"2024","unstructured":"Chen Z et al (2024) Enhanced theranostic efficacy of (89)Zr and (177)Lu-labeled aflibercept in renal cancer: a viable option for clinical practice. Mol Pharm 21(5):2544\u20132554","journal-title":"Mol Pharm"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06603-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06603-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06603-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:04:12Z","timestamp":1784282652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06603-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6603"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06603-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"501"}}